An FDA-approved medication can now treat Friedreich's ataxia, but health plan barriers and formulary exclusions keep many patients from receiving it.

Some of the market’s biggest winners start off as the smallest players. While trillion-dollar tech giants like the ...

The recent volatility in our stock appears to be driven by misconceptions and a lack of understanding about our business and long-term strategy, but I want to reassure our investors that there have ...

PTC Therapeutics, Inc. (NASDAQ:PTCT), a biopharmaceutical company focused on developing and commercializing novel medicines for rare disorders, finds itself at a critical juncture. With a promising ...

Jupiter Neurosciences (JUNS) issued a statement regarding recent market volatility and highlighted its planned Direct-to-Consumer product ...

Chief Scientific Officer Yoshitsugu Shitaka, Ph.D., won’t be so lucky. Astellas intends to create the new role of chief ...

Biogen’s Skyclarys is on course to becoming the first approved medicine for the inherited neurological disease Friedreich’s ataxia (FA) in the EU after it was recommended by the EMA’s human ...

After getting a green light from the European Commission, Biogen’s Skyclarys is the first approved medicine for the inherited neurological disease Friedreich’s ataxia (FA) in the EU.

The 200-page journal includes an article about the massacre on Dunlavin green in 1798, and other articles on Hollywood, ...

Alongside public hearings on Bill 83 to promote the practice of medicine within the public health and social services network, which begin tomorrow, the Point St. Charles Community Clinic and its ...

The presented content includes mentions of the omaveloxolone EU-approved label. Friedreich’s ataxia (FA) is a rare genetic disease that can affect children and adults and cause progressive ...